A coronavirus vaccine from Germany’s BioNTech has yielded positive trial results, generating immune defences in participants that were stronger than those of the average recovered Covid-19 patient, according to preliminary data released by the company.
In a clinical study run with pharmaceuticals group Pfizer in the US, 24 people between the ages of 18 and 55 who received two doses of the vaccine had “significantly elevated” antibodies within four weeks of their first injection.
https://www.ft.com/content/65d0b33a-f12a-4878-ac87-da4835683949
You can track them all here;
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker